Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.63 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.63 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.63 |
| ▸ | MAOA | P21397 | 1/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.63 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.63 |
| ▸ | ALPI | P09923 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | XIAP | P98170 | 1/20 | 0.62 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.62 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.58 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.58 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.58 |
| ▸ | CPA1 | P15085 | 2/20 | 0.54 |
| ▸ | CPB1 | P15086 | 1/20 | 0.54 |
| ▸ | CPA3 | P15088 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levamfetamine SCHEMBL4596702 | 1.00 | SLC6A2 (0.63) | SLC6A2TAAR1SLC6A4MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL3681578 | 1.00 | SLC6A2 (0.63) | SLC6A2TAAR1SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL1030966 | 1.00 | SLC6A2 (0.63) | SLC6A2TAAR1SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL19285614 | 0.98 | SLC6A2 (0.61) | SLC6A2TAAR1SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL1005247 | 0.98 | SLC6A2 (0.61) | SLC6A2TAAR1SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL19285616 | 0.98 | SLC6A2 (0.61) | SLC6A2TAAR1SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL30336931 | 0.98 | SLC6A2 (0.61) | SLC6A2TAAR1SLC6A4MAOASLC6A3 | |
| Levamfetamine SCHEMBL30083110 | 0.98 | SLC6A2 (0.61) | SLC6A2TAAR1SLC6A4MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL21158800 | 0.98 | SLC6A2 (0.61) | SLC6A2TAAR1SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL1005248 | 0.98 | SLC6A2 (0.61) | SLC6A2TAAR1SLC6A4MAOASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 516 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027043-A1 | EXTENDED RELEASE AMPHETAMINE TABLETS | TRIS PHARMA INC (US) | 2026-01-29 | — | — | US | claimed |
| US-20250352538-A1 | PHARMACEUTICAL RESINATE COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | RHODES PHARMACEUTICALS LP (US) | 2025-11-20 | — | — | US | claimed |
| US-20250352466-A1 | EXTENDED RELEASE AMPHETAMINE TABLETS | TRIS PHARMA INC (US) | 2025-11-20 | — | — | US | claimed |
| US-12458592-B1 | Extended release amphetamine tablets | TRIS PHARMA, INC. (US) | 2025-11-04 | — | — | US | claimed |
| US-20250064747-A1 | EXTENDED RELEASE AMPHETAMINE TABLETS | TRIS PHARMA, INC. (US) | 2025-02-27 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20250025432-A1 | METHODS FOR IMPROVING DRIVING BEHAVIOR | TRIS PHARMA INC (US) | 2025-01-23 | — | — | US | claimed |
| US-12076441-B2 | Extended release amphetamine tablets | TRIS PHARMA, INC. (US) | 2024-09-03 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| EP-3717452-B1 | PROCESS FOR PREPARING ACYLATED AMPHETAMINE DERIVATIVES | SpecGx LLC (US) | 2024-06-05 | — | — | EP | claimed |
| WO-2004091546-A2 | CENTRAL NERVOUS SYSTEM STIMULANT AND OPIOID ANTAGONIST COMBINATIONS | EURO-CELTIQUE S.A. (LU) | 2004-10-28 | — | — | WO | claimed |
| US-20040176378-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an amphetamine for the treatment of reduced blood flow to the central nervous system | PHARMACIA CORPORATION | 2004-09-09 | — | — | US | claimed |
| US-20030194439-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | MIDHA KAMAL K (BM) | 2003-10-16 | — | — | US | claimed |
| US-6555136-B2 | First, second and optionally third dosage units, with each dosage unit having a different drug release profile. | PHARMAQUEST, LTD. (BM) | 2003-04-29 | — | — | US | claimed |
| US-20020058061-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | MIDHA KAMAL K (CA) | 2002-05-16 | — | — | US | claimed |
| EP-1191924-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF (D-THREO)-METHYLPHENIDATE AND A SECOND CNS STIMULANT | Pharmaquest Limited (BM) | 2002-04-03 | — | — | EP | claimed |
| EP-1165054-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE | Pharmaquest Limited (BM) | 2002-01-02 | — | — | EP | claimed |
| US-6217904-B1 | MIXTURES; ADMINISTERING IN CYCLES | PHARMAQUEST LTD. (BM) | 2001-04-17 | — | — | US | claimed |
| WO-2000059481-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT | PHARMAQUEST LTD. (BM) | 2000-10-12 | — | — | WO | claimed |
| WO-2000059479-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE | PHARMAQUEST LTD. (BM) | 2000-10-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027043-A1 | EXTENDED RELEASE AMPHETAMINE TABLETS | SLC6A3, SLC6A2, SLC6A4 | SLC6A2 2/4885SLC6A3 1/4885TAAR1 238/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | SLC6A2 1338/4885SLC6A3 1329/4885TAAR1 142/4885 |
| US-20030194439-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | SLC18A1, SLC6A3, CRH | SLC6A2 10/4885SLC6A3 2/4885TAAR1 554/4885 |
| US-20020058061-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | SLC18A1, SLC6A3, CRH | SLC6A2 10/4885SLC6A3 2/4885TAAR1 554/4885 |
| US-20040176378-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an amphetamine for the treatment of reduced blood flow to the central nervous system | HTR2C, HTR2A, PTGS2 | SLC6A2 21/4885SLC6A3 60/4885TAAR1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.